158 related articles for article (PubMed ID: 36854495)
1. Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights.
Bimonte S; Palma G; Cascella M; Cuomo A
Anticancer Res; 2023 Mar; 43(3):993-1000. PubMed ID: 36854495
[TBL] [Abstract][Full Text] [Related]
2. Future Aspects for Cannabinoids in Breast Cancer Therapy.
Kisková T; Mungenast F; Suváková M; Jäger W; Thalhammer T
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987191
[TBL] [Abstract][Full Text] [Related]
3. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
4. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
Zhang L; Yu Q; Wu XC; Hsieh MC; Loch M; Chen VW; Fontham E; Ferguson T
Breast Cancer Res Treat; 2018 May; 169(1):175-187. PubMed ID: 29368311
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype.
Almeida CF; Teixeira N; Correia-da-Silva G; Amaral C
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011388
[TBL] [Abstract][Full Text] [Related]
7. Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.
Blasco-Benito S; Seijo-Vila M; Caro-Villalobos M; Tundidor I; Andradas C; García-Taboada E; Wade J; Smith S; Guzmán M; Pérez-Gómez E; Gordon M; Sánchez C
Biochem Pharmacol; 2018 Nov; 157():285-293. PubMed ID: 29940172
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the mechanism of action behind the anti-cancer properties of cannabinoids in ER
Amaral C; Trouille FM; Almeida CF; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2021 Jun; 210():105876. PubMed ID: 33722705
[TBL] [Abstract][Full Text] [Related]
9. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
10. Biosynthetic origins of unusual cannabimimetic phytocannabinoids in Cannabis sativa L: A review.
Welling MT; Deseo MA; Bacic A; Doblin MS
Phytochemistry; 2022 Sep; 201():113282. PubMed ID: 35718133
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
12. [New targeted compounds-biosynthesis of phytocannabinoids].
Gao P; Chen Y; Ke C; Yang X; Huang J
Sheng Wu Gong Cheng Xue Bao; 2021 Jun; 37(6):1968-1985. PubMed ID: 34227288
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
14. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
15. Medicinal Applications of Cannabinoids Extracted from Cannabis sativa (L.): A New Route in the Fight Against COVID-19?
Khalid S; Almalki FA; Hadda TB; Bader A; Abu-Izneid T; Berredjem M; Elsharkawy ER; Alqahtani AM
Curr Pharm Des; 2021; 27(13):1564-1578. PubMed ID: 33267756
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer: is there a treatment on the horizon?
Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
[TBL] [Abstract][Full Text] [Related]
17. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
18. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.
Elbaz M; Nasser MW; Ravi J; Wani NA; Ahirwar DK; Zhao H; Oghumu S; Satoskar AR; Shilo K; Carson WE; Ganju RK
Mol Oncol; 2015 Apr; 9(4):906-19. PubMed ID: 25660577
[TBL] [Abstract][Full Text] [Related]
20. Constituents of Cannabis Sativa.
Rock EM; Parker LA
Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
